Pharmacokinetics of Peginterferon Alfa-2b in Participants With Moderate and Severe Renal Impairment (P05655)

Inclusion Criteria: * Body Mass Index (BMI) between 19 to 40 kg/m\^2, inclusive * Moderate renal impairment and severe renal impairment and/or end-stage renal disease (ESRD) who may require hemodialysis and normal renal function * Free of any clinically significant disease (except those related to renal disease and comorbid conditions) that requires a physician's care and would interfere with the study * Females of reproductive potential must have used a medically accepted method of contraception for three months prior to screening and must agree to use an accepted contraceptive method during and for two months following the study * Males must agree to use a medically accepted method of contraception during the trial and for 3 months after the study Exclusion Criteria: * Pregnant, intend to become pregnant, or breastfeeding * Surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug * History of any infectious disease within 4 weeks prior to study drug administration that affects ability to participate in the study * Positive for hepatitis B surface antigen, and/or for human immunodeficiency virus (HIV) antibodies. Healthy participants positive for hepatitis C antibodies * Previously received PegIntron®, Sylatron®, and/or Pegasys * More than 10 cigarettes or equivalent tobacco use per day * History of malignancy * Hypothyroidism or hyperthyroidism * History of depression requiring treatment with psychotherapy or medication * History of suicidality or at risk of self-harm or harm to others * History of autoimmune disorder requiring medical therapy * Immune mediated renal insufficiency * Removal of a kidney (healthy participants) or functioning renal transplant (participants with renal impairment)